Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma-Reference-Cited by-同舟云学术

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

Published:2013-07 Issue:1 Volume:24 Page:75-89
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Brockmann Markus,Poon Evon,Berry Teeara,Carstensen Anne,Deubzer Hedwig E.,Rycak Lukas,Jamin Yann,Thway Khin,Robinson Simon P.,Roels Frederik,Witt Olaf,Fischer Matthias,Chesler Louis,Eilers Martin

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference40 articles.

1. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets;Beltran;Cancer Discov.,2011

2. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter;Bouchard;Genes Dev.,2001

3. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage;Brodeur;Science,1984

4. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice;Bruggeman;Genes Dev.,2005

5. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma;Chanthery;Science translational medicine,2012

Cited by 249 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer;Current Cancer Drug Targets;2024-09

2. Association with TFIIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA polymerase II;eLife;2024-08-23

3. Association with TFIIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA polymerase II;eLife;2024-08-23

4. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma;Cancers;2024-08-17

5. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer;Nature Communications;2024-08-05